Cyclerion (NASDAQ: CYCN) CFO buys 25,000 shares in cash exercise
Rhea-AI Filing Summary
Cyclerion Therapeutics, Inc. (CYCN) reported that its Chief Financial Officer, Rhonda M. Chicko, exercised stock options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paid in cash. These options, granted on August 7, 2025 under the 2019 Equity Incentive Plan and originally vesting over time, had all remaining vesting accelerated by the board on July 17, 2026. After the exercise, Chicko directly holds 25,018 shares of common stock and no remaining options from this specific grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 25,000 shares
Net Buy
2 txns
Insider
CHICKO RHONDA M.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase F1 | 25,000 | $0.00 | $0.00 |
| Exercise | Common Stock, no par value F1 | 25,000 | $2.355 | $59K |
Holdings After Transaction:
Option to Purchase — 0 shares (Direct);
Common Stock, no par value — 25,018 shares (Direct)
Footnotes (1)
- F1. The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price.
Key Figures
Options Exercised: 25,000 shares
Exercise Price: $2.355 per share
Post-Transaction Holdings: 25,018 shares
+3 more
6 metrics
Options Exercised
25,000 shares
Shares of common stock underlying options exercised on August 14, 2026
Exercise Price
$2.355 per share
Exercise price of the option grant covering 25,000 shares
Post-Transaction Holdings
25,018 shares
Total common stock directly held by the CFO after the transaction
Option Grant Size
25,000 shares
Maximum number of shares under the option granted August 7, 2025
Option Expiration Date
2035-08-06
Expiration date of the option that was exercised in full
Accelerated Vesting Date
July 17, 2026
Date the board accelerated vesting of all then-unvested options
Key Terms
2019 Equity Incentive Plan, vest ratably, exercise price, expiration date
4 terms
2019 Equity Incentive Plan financial
"to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan"
vest ratably financial
"the remaining 16,250 shares were to vest ratably in monthly installments"
exercise price financial
"conversion_or_exercise_price": "2.3550""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2035-08-06""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What insider transaction did CYCN’s CFO report on this Form 4?
Cyclerion’s CFO Rhonda M. Chicko exercised options for 25,000 shares of common stock on August 14, 2026 at an exercise price of $2.355 per share, paying cash to the company and converting the options into directly held common stock.
What was the exercise price for the CYCN stock options used by the CFO?
The exercised Cyclerion stock options had an exercise price of $2.355 per share. On August 14, 2026, the CFO exercised all 25,000 option shares and paid the full purchase price in cash directly to Cyclerion Therapeutics, Inc.
When were the CYCN options originally granted and under what plan?
The options were granted on August 7, 2025 to purchase up to 25,000 shares of Cyclerion common stock under the company’s 2019 Equity Incentive Plan. They included immediate and monthly vesting components before later being fully accelerated.
Did CYCN’s board take any action affecting the CFO’s option vesting?
Yes. On July 17, 2026, Cyclerion’s Board of Directors accelerated in full the vesting of all then unvested options held by the CFO under this grant, allowing her to exercise the entire 25,000-share option position on August 14, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
